کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8536304 | 1560808 | 2018 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Sodium glucose cotransporters inhibitors in type 1 diabetes
ترجمه فارسی عنوان
دیابت نوع 1، مهارکننده های گلوکز سدیم است
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
داروشناسی
چکیده انگلیسی
Sodium glucose cotransporter inhibitors (SGLTi) are oral hypoglycemic drugs that reduce renal glucose re-uptake and induce glycosuria. SGLTi have been successfully tested in large randomized clinical trials for type 2 diabetes, and several molecules have been approved in this setting by the international pharmaceutical agencies. Additionally, recent evidence has shown that SGLTi may be useful also in type 1 diabetes (T1D). Indeed, these drugs can be used as an ancillary to insulin to improve glycemic control and reduce insulin dosage, and such regimens have been associated with a lower rate of hypoglycemic episodes. The pharmacological effects of SGLTi therapy are described herein, and we also discuss the future use of SGLTi in T1D.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Pharmacological Research - Volume 133, July 2018, Pages 1-8
Journal: Pharmacological Research - Volume 133, July 2018, Pages 1-8
نویسندگان
Sergio Dellepiane, Moufida Ben Nasr, Emma Assi, Vera Usuelli, Teresa Letizia, Francesca D'Addio, Gian Vincenzo Zuccotti, Paolo Fiorina,